Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 19, Issue 10, Pages 1469-1472Publisher
INFORMA HEALTHCARE
DOI: 10.1517/13543770903059281
Keywords
allergy; asthma; PF-03526299; R-343; Syk kinase
Categories
Ask authors/readers for more resources
The subject of this application is N(4)-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N(2)-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine xinafoate salt, as well as inhalant formulations of the salt and a process for the preparation of the salt. This salt is probably R-343, a Syk kinase inhibitor being developed under license by Pfizer, an inhaled formulation of which is in Phase I development for the treatment of asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available